2016年CIOMS伦理指南后,少数药物实用性试验可能符合豁免知情同意的条件
该研究调查了2016年7月1日至2018年6月30日欧盟临床试验注册库中所有IV期「进行中」的随机对照试验,以识别可能具有高实用性且符合2016年CIOMS三项条款(知情同意不可行、试验具有高社会价值、对参与者无风险或风险最小)的药物试验。在638项IV期试验中,420项为随机对照试验,其中21项(5%)为实用性试验候选;15项试验的研究者自评了实用性程度,14项为高度实用性,其中8项符合三项CIOMS条款。患者和伦理委员会对若干试验的评估不一致。结论认为,符合修改或豁免知情同意条件的低风险实用性随机对照试验很少,欧洲监管机构应考虑修订现行法规并鼓励开展此类试验。
要点
- 在638项IV期试验中,420项为随机对照试验,21项(5%)为实用性试验候选。
- 21项候选试验中15项的研究者自评实用性,其中14项为高度实用性。
- 14项高度实用性试验中8项符合三项CIOMS条款,患者与伦理委员会评估不一致。
核心结论
- 符合修改或豁免参与者知情同意条件的低风险实用性随机对照试验很少。
- 作者建议欧洲监管机构应考虑修订现行法规并鼓励开展此类试验。
研究设计与样本
- 这是一项对2016年7月1日至2018年6月30日欧盟临床试验注册库中所有IV期「进行中」随机对照试验的调查。
- 排除标准包括:罕见病试验、健康志愿者试验(评估疫苗者除外)、设盲(单盲或双盲)试验、单中心试验、可预期引导患者偏好某一干预措施的试验及其他原因。
- 由试验研究者使用PRECIS-2工具自评随机对照试验的实用性程度。
- 被认为高度实用性的试验的研究者评估三项CIOMS条款的符合情况。
- 7名患者评估随机对照试验的社会价值;11个研究伦理委员会的33名成员评估试验的社会价值及对参与者的风险是否不超过最小风险。
主要发现
- 在638项IV期试验中,420项为随机对照试验,其中21项(5%)为实用性试验候选。
- 21项候选试验中15项的研究者自评了试验的实用性程度,其中14项为高度实用性。
- 14项高度实用性试验中8项符合三项CIOMS条款。
- 患者和伦理委员会对若干试验的评估不一致。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: European regulations do not allow modification or waiver of informed consent for medicines randomized controlled trials (RCTs) where the three 2016 Council for International Organizations of Medical Sciences (CIOMS) provisions are met (consent would be impractical or unfeasible, yet the trial would have high social value and pose no or minimal risk to participants). We aimed to identify whether any such trials of medicines were being conducted in Europe. STUDY DESIGN AND SETTING: This is a survey of all phase 4 "ongoing" RCTs on the EU clinical trial register between July 1, 2016 and June 30, 2018, to identify those with potentially high levels of pragmatism. Trials that were excluded were as follows: those conducted on rare diseases; conducted on healthy volunteers (except those assessing vaccines); masked (single-, double-blind) trials; single-center trials; those where one could expect to lead patients to prefer one intervention over the other; and miscellaneous reasons. The degree of pragmatism of the RCTs was self-assessed by trials' investigators by means of the PRECIS-2 tool. Investigators of those trials considered to be highly pragmatic assessed the fulfillment of the three CIOMS provisions. Seven patients assessed the social value of the RCTs. Finally, 33 members of 11 research ethics committees (RECs) assessed the social value of the trials and whether they posed no more than minimal risk to participants. Investigators, patients, and REC members assessed the fulfillment of the CIOMS provisions as "yes," "not sure" or "no." RESULTS: Of the 638 phase 4 trials, 420 were RCTs, and 21 of these (5%) were candidates to be pragmatic. Investigators of 15 of these 21 RCTs self-assessed their trial's degree of pragmatism: 14 were highly pragmatic. Of these 14, eight fulfilled the three CIOMS provisions. Assessments by patients and RECs were inconsistent for several trials. CONCLUSIONS: We found few low-risk participant-level pragmatic RCTs that could be suitable for modified or waived participants' informed consent. European regulators should consider amending the current regulation and encouraging the conduct of such trials.
引用
- Dal-Ré R, Avendaño-Solà C, de Boer A, et al. A limited number of medicines pragmatic trials had potential for waived informed consent following the 2016 CIOMS ethical guidelines. J Clin Epidemiol. 2019. PMID: 31212001. doi:10.1016/j.jclinepi.2019.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。